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Abstract
Background: Randomised controlled trials (RCTs) need to be reported so that their results can be unambiguously
and robustly interpreted. Binary outcomes yield unique challenges, as different analytical approaches may produce
relative, absolute, or no treatment effects, and results may be particularly sensitive to the assumptions made about
missing data. This review of recently published RCTs aimed to identify the methods used to analyse binary primary
outcomes, how missing data were handled, and how the results were reported.
Methods: Systematic review of reports of RCTs published in January 2019 that included a binary primary outcome
measure. We identified potentially eligible English language papers on PubMed, without restricting by journal or
medical research area. Papers reporting the results from individually randomised, parallel-group RCTs were included.
Results: Two hundred reports of RCTs were included in this review. We found that 64% of the 200 reports used a
chi-squared-style test as their primary analytical method. Fifty-five per cent (95% confidence interval 48% to 62%)
reported at least one treatment effect measure, and 38% presented only a p value without any treatment effect
measure. Missing data were not always adequately described and were most commonly handled using available
case analysis (69%) in the 140 studies that reported missing data. Imputation and best/worst-case scenarios were
used in 21% of studies. Twelve per cent of articles reported an appropriate sensitivity analysis for missing data.
Conclusions: The statistical analysis and reporting of treatment effects in reports of randomised trials with a binary
primary endpoint requires substantial improvement. Only around half of the studied reports presented a treatment
effect measure, hindering the understanding and dissemination of the findings. We also found that published trials
often did not clearly describe missing data or sensitivity analyses for these missing data. Practice for secondary
endpoints or observational studies may differ.
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Background
Randomised controlled trials (RCTs) are commonly con-
ducted to provide an evidence base for current and new
treatments, inform evidence-based healthcare, and im-
prove patients’ outcomes and welfare. Binary outcomes
are those that can take only one of two values, such as
treatment failure or success, or mortality (dead or alive).
Many trials have a binary outcome as one of the key
measures used to compare treatments. Charles et al. [1]
found that around half of trials calculated their sample
size based on a binary outcome. Trials using binary out-
comes have different statistical and other considerations
to trials using other outcome types, such as continuous
and time-to-event.
As for all outcomes, the analysis and reporting of the
findings of binary outcomes is clearly a key aspect of
good scientific practice and is critical for maximising the
value of the research. However, to our knowledge, little
research has been carried out on the analysis of binary
endpoints in clinical trials. This is surprising, as their
use has implications for the analysis planned and the
reporting. Numerous statistical analysis approaches exist
for analysing binary outcomes, such as logistic regression
and, more recently, Poisson regression with appropriate
calculation of standard errors. Anecdotally, statistical
analysis methods that do not produce an estimate of the
effect size and only produce a p value (e.g. chi-squared-
style test) seem to be more commonly used. Related to
this, the target difference used in the sample size calcu-
lation can be based on a relative (e.g. risk ratio of 0.75)
or absolute (e.g. reduction from 80 to 60%) difference in
the treatment effect of the binary outcome. Statistical
adjustment for a covariate when analysing binary out-
comes (and also time-to-event outcomes) should be con-
sidered carefully as unadjusted and adjusted analyses
estimate different treatment effects [2–4].
The Consolidated Standards of Reporting Trials
(CONSORT) statement [5] recommends reporting both
the relative treatment effect (e.g. odds ratio or relative
risk) and an absolute treatment effect (e.g. risk differ-
ence) for binary outcomes. Presenting both effects argu-
ably gives a more complete picture of the results and
their implications than reporting just one. For example,
the doubling of an event rate (i.e. relative risk) will have
more relevance for public health if the outcome has a
high overall risk than if the outcome has a low overall
event rate. For a given relative treatment effect, the ab-
solute risk difference would also be much larger if the
event had a high overall event rate, compared with a low
overall event rate. Nevertheless, most statistical analysis
methods that do directly produce an effect size estimate
provide only one estimate, usually a relative difference.
Missing data are also handled differently for binary
and other outcomes. Missing data in clinical trials are
commonly analysed using available cases. Imputation
methods, including simple imputation, multiple imput-
ation, and worst-case scenarios, are used less frequently
in primary analyses [6–8]. All approaches for missing
data make strong, untestable assumptions about the
underlying missing data mechanism. It is unclear if and
how such analyses are done. Sensitivity analyses to assess
the impact of these assumptions are recommended, but
rarely used [6–8].
How binary outcomes are analysed in clinical trials
and the findings reported is therefore of much interest.
In this paper, we report a systematic review of the statis-
tical analysis of binary outcomes in recently published
RCTs. We focus on the methods used to analyse binary
primary outcomes, how missing data are handled, and
how the findings are reported.
Methods
The literature was searched for reports of RCTs pub-
lished in January 2019 (e-publication or print). Studies
were eligible if they reported the findings of rando-
mised controlled trials with a binary primary out-
come. We did not limit the inclusion criteria to any
particular condition, intervention or patient group.
We excluded papers classed as meta-analyses, com-
ments, letters, editorials, or news; animal experiments;
and studies not in humans. We did not restrict the
search by journal or disease area. Only articles writ-
ten in English were considered.
We developed a search strategy for PubMed (see
Additional file 1: ‘Summary of search strategy and papers
identified’ for full details of the search terms used). The
search was performed on 18 April 2019 by the lead au-
thor (IR), to allow sufficient time for indexing.
The target sample size was 200 papers, as this was
considered a sufficiently large number of papers to
produce a generalisable assessment of current prac-
tice, in line with similar studies. This target was also
considered sufficient to let us measure binary out-
comes to a confidence interval (CI) width of 0.08 to
0.14, depending on the event rate, based on Wilson’s
CI method [9].
Titles and abstracts were screened by the lead author
(IR) to identify reports of two-arm, parallel-group, indi-
vidually randomised trials with a binary primary end-
point. The primary endpoint had to be clearly described
as such in the paper, used to determine the sample size
calculation, or was referred to in the aims and objectives
of the paper. We excluded cluster, cross-over, and
multi-arm (> 2 arms) trials and papers reporting a prin-
cipal analysis based on time-to-event data. We also ex-
cluded pilot and feasibility studies and papers that were
not primary reports of clinical trials.
Rombach et al. BMC Medicine          (2020) 18:147 Page 2 of 8
Titles and abstracts were screened in chronological
order (by date of publication listed in EndNote) until
200 eligible papers had been identified.
We used a standardised data extraction form to collect
information (see Additional file 2 for a list of items) on
the characteristics of the included studies, the analysis,
and reporting approaches.
All authors contributed to the development of the data
extraction forms (using Microsoft Excel) and piloted
them on a number of papers. All authors contributed to
the data extraction, and each reviewer confirmed that
their allocated papers matched the inclusion criteria,
based on a full-text review. To assess the reliability of
the extraction, duplicate extraction was performed for
10% of the sample. Discrepancies were resolved by the
lead author. Single data extraction was performed for
the remaining studies.
Information on study characteristics (including disease
area, journal, trial design, single vs. multicentre, sample
size, and funding), principal analysis methods, additional
analyses of the primary endpoint, amounts of missing
data, and participants included in the analysis was ex-
tracted from the final set of papers. We assessed whether
relative and absolute risks and their CIs were presented
and whether p values were given. We also extracted the
method of handling missing data in the principal ana-
lysis and whether relevant sensitivity analyses were per-
formed. Full details of all items extracted can be found
in the supplementary material.
We generated descriptive statistics using frequency
and percentage for categorical data and median, inter-
quartile range, mean, and standard deviation for con-
tinuous data. Frequencies and percentages were also
generated. We also collected data on how many studies
provided p values for the comparison between groups.
95% confidence intervals (CI) using Wilson's methods
were calculated for the key binary measures of inter-
est. The association between journal impact factors and
whether or not at least one treatment effect was re-
ported were based on a logistic regression model; an odds
ratio with 95% CI was calculated. Impact factor was used
as the single continuous covariate in this model.
Analyses and summaries were generated in Stata/IC
version 15.
Results
Figure 1 shows the number of articles obtained from the
literature search, articles excluded and why, and articles
included in the study. Two hundred articles, covering a
wide range of disease areas and journals, were included
in this review.
The most commonly included disease areas were ob-
stetrics and gynaecology (n = 32, 16%), gastroenterology,
oncology, and infectious diseases (each n = 24,
12%). Other medical specialities, including cardiology,
critical care, dermatology, paediatrics, public health and
policy interventions were also covered by the studies.
The studies were published in journals with impact fac-
tors ranging from 0.4 to 70.7, with a mean of 8.7 (stand-
ard deviation 15.8). The median was 3.4, with an
interquartile range from 2.2 to 6.0.
The double data extraction for 10% of the included pa-
pers demonstrated good agreement between the re-
viewers. Seventeen key items were extracted for each of
the 20 papers. Less than 10% discrepancies were found
(31/340), and these tended to be very minor.
Additional characteristics of the studies included in
this review, i.e. trial design, sample size, whether they in-
cluded multiple centres, and the main funding source,
are shown in Table 1.
Two of the 200 studies reported that no analyses of the
primary endpoint were performed. Of the 198 studies
that reported an analysis, almost two thirds (n = 127, 64%)
reported using chi-squared-style tests as their principal
analysis method. Logistic regression was reported in only
22 (11%) papers. The principal analysis method was not
clear in 24 (12%) papers based on the main text. Ninety
per cent of the abstracts did not indicate the analytical
methods used for the primary endpoint. Details of the
analyses reported are provided in Table 2. Adjustment of
the principal analysis was reported in 32 (18%) of the 174
studies that had specified the analytical method.
In total, 41 papers (21%, Wilson’s confidence interval
(CI) 15 to 27%) used a primary analytical method that
was able to produce a treatment effect estimate.
Seventeen per cent of studies reported both an ad-
justed and unadjusted analysis for the primary binary
endpoint.
Table 3 shows the number of studies that reported ab-
solute effects, relative effects, or both, referring to all
analyses of the primary binary endpoint, and not just the
principal analysis. One hundred and nine studies of the
198 that reported a statistical analysis (55%, Wilson’s
95% CI 48 to 62%) provided at least one treatment ef-
fect estimate. A p value for a test of a difference between
the groups was given in 164 (83%, Wilson’s 95% CI 77
to 87%) studies. Twenty studies provided treatment ef-
fects without p values. A higher journal impact factor
was statistically significantly associated with at least one
treatment effect estimate (either relative or absolute) be-
ing reported, odds ratio = 1.15 (95% CI 1.05 to 1.28).
Some primary follow-up data were missing in at least
140 (70%, Wilson’s 95% CI 63 to 76%) studies, although
the extent of missing data was only clear in 118 (59%)
studies. The studies that had missing primary outcome
data and were clear about how much missing data there
was had a median missing data rate of 5% (interquartile
range 2 to 14%).
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Table 4 shows the approaches used to handle missing
data in the primary analyses and whether an appropriate
sensitivity analysis was performed for missing data, if
any existed. Of the 140 studies that reported missing
data, 96 (69%) reported using an available case analysis;
imputation and best/worst case scenarios were reported
in 30 studies (21%).
Seventeen of the relevant papers where missing data
were reported (12%, Wilson’s 95% CI 8 to 19%) per-
formed an appropriate sensitivity analysis for missing
data.
Discussion
Our review showed that the statistical analysis and
reporting of treatment effects in reports of randomised
trials with a binary primary endpoint requires substantial
Fig. 1 PRISMA flow chart for the literature search
Table 1 Characteristics of the 200 studies included in this
review




Size Median = 145, interquartile range = 82–400
Multicentre Yes 110 (55%)
No 83 (42%)
Unclear 7 (4%)
Funding Public, charity, or public and charity 68 (34%)
Solely industry 38 (19%)
Others (include combinations) 40 (20%)
No stated funding 54 (27%)
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improvement. Most of the trials used a principal analysis
method that did not provide an estimate of the treat-
ment effect. Less than half of the reviewed studies re-
ported an estimate of the treatment effect from any
analysis of the primary endpoint (principal or second-
ary). Disappointingly, 12% did not clearly state which
principal analysis method was used. Only 8% reported
both a relative and absolute treatment effect with corre-
sponding CIs as recommended by the CONSORT 2010
statement [5]. This low adherence to the CONSORT
reporting guideline is perhaps disappointing, considering
that many biomedical journals endorse the CONSORT
guideline. However, it probably reflects, at least partially,
the complexity of implementing the guideline.
Possible solutions exist to remedy these shortcomings
in conduct and reporting. The most commonly used
principal analysis method was a chi-squared-style test.
The use of these tests should be discouraged in favour
of alternative statistical analysis methods such as logistic
or binomial regressions, which produce estimates of the
effect size. This may reflect a limitation in medical statis-
tics training to health professionals, which can over-
emphasise statistical testing to the detriment of a more
rounded approach to statistical inference. It may also re-
flect a more profound problem in modern research:
innovation is more likely to be rewarded than evaluation
and adoption of better practice. Strangely, although
quantification of the treatment effect and uncertainty is
the overwhelming practice in trial meta-analyses [10], it
is often not done in trials themselves.
To meet the concerns raised here, we recommend
using a statistical analysis method that estimates the
magnitude of the treatment effect and quantifies the un-
certainty (e.g. CI) to analyse the primary binary outcome
of a randomised trial, whether as the principal method
Table 2 Principal analysis method reported for the primary
binary outcome used in the 200 included studies
Reported in the main
text (n = 200)
Reported in the
abstract (n = 200)
Chi-squared-style tests1 127 (64%) 13 (7%)
Logistic regression 22 (11%) 3 (2%)
Looking at confidence
interval limits2
8 (4%) 3 (2%)
Binomial regression 7 (4%) 1 (1%)
Others3 10 (5%) 0 (0%)
Not reported 24 (12%) 180 (90%)
No analysis4 2 (1%) 0 (0%)
1Including Fisher’s exact and Mantel-Haenszel test
2
‘Looking at confidence intervals’ refers to where the assessment of non-
inferiority was made by comparing the upper or lower limits of the confidence
interval, as appropriate, to the non-interiority margin
3These include Poisson models, exact binomial test, tests for non-inferiority
(including Farrington-Manning), and Newcombe’s method
4One study reported no events and therefore did not perform the planned
principal analysis. One study described a composite primary endpoint, which
was not reported in the paper; the components of the composite endpoint
were reported separately
Table 3 Reporting of treatment effects, confidence intervals,






Reporting of statistical analysis
Any treatment effect measure1 109 (55%) 75 (38%)
No treatment effect measure,
p value only
75 (38%) 86 (43%)
No statistical analysis result reported 14 (7%) 37 (19%)
Reporting of treatment effects2
Relative treatment effect only
(point estimate)
55 (28%) 42 (21%)
Point estimate and CI 55 (28%) 42 (21%)
Absolute treatment effect only
(point estimate)
33 (17%) 26 (13%)
Point estimate and CI 30 (15%) 25 (13%)
Both relative and absolute treatment
effects reported (point estimate)3
18 (9%) 7 (4%)
Point estimates and CIs 16 (8%) 6 (3%)
Numbers refer to any analyses for the primary binary outcome in the report
and are not limited to the only principal analysis
CI confidence interval
1Including papers that reported an estimate of an absolute or relative effect
measure (point estimate and/or confidence interval)
2Three studies reported confidence intervals, but no point estimate (full text
only). These studies were counted in ‘reporting of statistical analysis’, but not
in ‘reporting of treatment effects—relative/absolute treatment effects only
(point estimate)’ and ‘both relative and absolute treatment effects reported
(point estimate)’
3Where both absolute and relative treatment effect estimates were presented,
different statistical methods were used to obtain these estimates; no papers
described that transformations to obtain an absolute effect from a relative
one, or vice versa, were used
Table 4 Handling of missing data in the principal analysis of
the 140 studies that reported some missing data in their
primary outcome and performed an analysis
Approach to handling missing data in the principal analysis
Available cases 96 (69%)
Multiple imputation 9 (6%)
Worst-case/best-case scenario 18 (13%)
Last observation carried forward 2 (1%)
Other1 1 (1%)
Unclear 14 (10%)
Performance of appropriate2 sensitivity analysis for
missing data
17 (12%)
1In one study, missing outcomes were imputed by independent assessors
using a pre-defined set of rules provided in a supplementary appendix
2Defined as an analysis that varies the assumptions made about the
underlying missing data mechanism
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or a pre-specified secondary analysis. This is eminently
achievable. Even for smaller trials with fewer events, the
magnitude of the treatment effect can be readily quanti-
fied and uncertainty with CIs calculated as long as there
is at least one event [11, 12]. Reporting of the corre-
sponding p value also has its place, at least for the prin-
cipal analysis of the primary outcome [13].
Methods that allow quantification of the treatment ef-
fect and related uncertainty are readily available, such as
the calculation for the unadjusted odds ratio and its CI
[14] and logistic regression for the adjusted odds ratio.
Reporting the magnitude of the treatment effect is vital
for communicating the trial findings in a meaningful,
transparent way to all stakeholders, particularly patients
and members of the public. Just identifying a statistically
significant difference is not enough to confirm action
[15], and finding the absence of evidence of a statistical
difference is not enough to conclude no difference be-
tween treatments. The crude dichotomisation of findings
has thus been heavily criticised, and alternative ap-
proaches and remedies suggested [16]. Perhaps, the most
successful initiative in this area has been driven by jour-
nals like the BMJ and others, who early on promoted
reporting the uncertainty around estimates (typically
with a CI) [12]. However, trial reports often still do not
state an estimate of the treatment effect and/or quantify
the uncertainty around the estimate. Presumably, many
researchers feel the reader can calculate the uncertainty
themselves by looking at the observed event rate in each
group. However, this stance is not acceptable in our
view, given the importance of this value as the main
study finding.
Different audiences may be more used to interpreting
relative or absolute risk, although effects tend to be
overestimated when presented as relative risks [5]. The
practicalities of calculating both relative and absolute
treatment effects are surprisingly complex. The statis-
tical methods typically used directly calculate one or the
other. Some researchers may then believe that they need
to use different statistical methods to be able to report
both relative and absolute treatment effects, which was
the approach chosen in all studies that presented both
relative and absolute treatment effect estimates. Per-
forming more analyses raises multiplicity issues: the
chance of obtaining spurious significant results increases
with the number of tests performed, as does the poten-
tial for selecting the more favourable results if the prin-
cipal analysis is not pre-specified. Recent work on
sample size calculations [17, 18] has highlighted the
need to clarify what the target difference is when design-
ing the trial.
Only 8% of the included studies reported both an ab-
solute and relative treatment effect with corresponding
CIs, as recommended by the CONSORT guidelines [5].
Similarly, only 10% reported the statistical analysis
method used to analyse the primary outcome in the ab-
stract. If the CONSORT guidelines are rarely followed in
these regards, either adherence should be more strongly
encouraged by journals and peer reviewers, or they
should be relaxed. Although it may be helpful to present
both relative and absolute treatment effects, providing
estimates of the event rates by treatment arm with ei-
ther type of treatment effect estimate can arguably also
convey the full picture of the intervention without re-
quiring two formal tests. Most statistical analysis
methods implicitly or explicitly assess a relative treat-
ment effect. They tend to be more precise in our experi-
ence, at least in terms of detecting a statistically
significant difference, than methods that assess absolute
effects. When interpreting relative treatment effects, re-
searchers should bear in mind that odds ratios tend to
be higher than risk ratios (in some cases substantially
so), and thus, for any relative effect bearing in mind the
anticipated control risk rate is critical [19–21].
The extent of missing data was generally insufficiently
described, leading to a lack of clarity regarding how
much outcome data were missing, and hence how reli-
able the results were. When data were missing, appropri-
ate sensitivity analyses based on varying assumptions
about the missing data mechanism, including worst-case
scenarios, were rarely performed. Sensitivity analyses for
missing data are particularly important for binary out-
comes as even small changes in the numbers of events
by treatment arm can change the treatment estimates or
even the trial conclusions.
The large number of recently published clinical trial
reports in a range of journals and clinical areas reviewed
is a strength of the methodology used. The papers in-
cluded are therefore representative of current practice
and show that there are problems in published reports
across journals and irrespective of markers of journal
prestige (e.g. higher impact factors). While there is some
indication that treatment effects are more likely to be re-
ported in higher-impact journals, there was room for
improvement in terms of reporting of statistical
methods, treatment effect estimates, and missing data
across the board. Our study was not designed in order
to be able to look at the difference between particular
subgroups, such as disease area or source of funding.
Further research should investigate if there are differ-
ences in the analysis and reporting of binary outcomes
by study characteristics so that focus and any strategies
for improving reporting can be directed where they may
be needed most.
There are a number of limitations to this work, which
we aimed to mitigate where possible. We performed our
database search in April 2019 for papers published in
January 2019. It is possible that not all relevant papers
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were indexed by then, causing us to unintentionally ex-
clude some papers from the review. However, due to our
fairly large sample and otherwise broad inclusion cri-
teria, we do not anticipate that this limitation will have
biased our findings. As the target sample size was set at
200 papers, we did not include all of the papers identified
by the literature search in the final review. However, we
screened papers in their publication date order, as col-
lected in EndNote, which we anticipate will have pre-
vented bias. For most of the papers, data were extracted
by only one reviewer. We performed double extraction by
two independent reviewers for around 10% of the papers,
which showed good agreement on the key items of treat-
ment effects reported, statistical tests performed, and
missing data. Although the sample size was substantial,
the 200 studies may not reflect the full range of practices,
particularly for less-researched areas. Previous reviews
have demonstrated that the choice of outcome and prac-
tice can vary substantially by clinical area [1, 22, 23].
Our review was limited to English language publica-
tions. Although this is likely to be representative of most
RCTs, practice for RCTs reported only in other
languages may differ. We included only reports with pri-
mary binary outcomes. Although we have not investi-
gated practice for secondary binary outcomes, we
assume that the methods used for secondary outcomes
will rarely be superior to those used for primary out-
comes. However, we believe that the included studies do
reflect current practice analysing binary outcomes in
general.
More generally, this review did not consider other out-
come types, such as time-to-event, ordinal, and continu-
ous outcomes. In our view, similar reviews of these
other outcomes would also be highly beneficial. We also
restricted the review to randomised trials with a two-
arm parallel-group design. Current practice for other
RCT designs and observational studies evaluating treat-
ments may differ.
Conclusions
This study identified substantial room for improve-
ment in the analysis and reporting of binary primary
outcomes in RCTs. Binary endpoints were often ana-
lysed with a method that did not provide an estimate
of the treatment effect or its related uncertainty inhi-
biting interpretation of findings. Published trials
often did not clearly describe missing data or perform
sensitivity analyses for these missing data. The main
limitation of this research was its focus on binary pri-
mary outcomes in RCTs, excluding secondary out-
comes. Our findings suggest that the analysis and
reporting of binary endpoints in RCTs needs to
improve.
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